Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.48 |
| ▸ | RXRB | P28702 | 2/20 | 0.48 |
| ▸ | DDT | P30046 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121673 | 0.88 | AKR1C3 (0.61) | AKR1C3AKR1C2EPHX2HDAC1HDAC6 | |
| SCHEMBL28160262 | 0.85 | HDAC6 (0.51) | AKR1C3AKR1C2HDAC1HDAC6KMO | |
| SCHEMBL28334899 | 0.85 | DDT (0.54) | AKR1C3AKR1C2HDAC1HDAC6KMO | |
| SCHEMBL2524411 | 0.84 | RXRA (0.50) | AKR1C3AKR1C2EPHX2HDAC1HDAC6 | |
| SCHEMBL4229287 | 0.84 | AKR1C3 (0.55) | AKR1C3AKR1C2EPHX2HDAC1HDAC6 | |
| SCHEMBL13601671 | 0.78 | RORC (0.47) | AKR1C3AKR1C2EPHX2PDK2MRGPRX4 | |
| SCHEMBL2597833 | 0.78 | HSD11B1 (0.51) | PDK2 | |
| SCHEMBL28672486 | 0.78 | AKR1C3 (0.49) | AKR1C3AKR1C2EPHX2HDAC1HDAC6 | |
| SCHEMBL2213546 | 0.76 | KMO (0.73) | KMOPDK2FOLH1RXRARXRB | |
| SCHEMBL30259065 | 0.76 | KMO (0.73) | KMOPDK2FOLH1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| EP-2375904-A1 | BIARYL CARBOXAMIDES | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010077624-A1 | BIARYL CARBOXAMIDES | MERCK SHARP & DOHME CORP. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | AKR1C3 4744/4885AKR1C2 4542/4885EPHX2 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.